课题基金 / 基金详情

Objectively monitoring neurodegenerative disease progression: speech as a clinical marker

Objectively monitoring neurodegenerative disease progression: speech as a clinical marker
客观监测神经退行性疾病进展:言语作为临床标记
批准号:
nhmrc : 1012302
负责人:
A/Pr Adam Vogel
金额:
$20.15万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Early Career Fellowships
财政年份:
2011
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2011-01-01 至 2015-12-31

项目摘要

项目成果

A/Pr Adam Vogel的其他基金

相似基金

相关文献

中文摘要
翻译
在某些神经退行性疾病如亨廷顿病或痴呆症中,如果不使用昂贵的侵入性评估技术,很难监测疾病进展。然而,通过反复记录和分析患者的言语(我们如何说话,而不是我们说了什么),我们建立了大脑如何运作和随时间变化的图片。这将带来更加个性化的方法,在正确的时间为正确的患者提供更有效的治疗。
英文摘要
It is difficult to monitor disease progression in some neurodegenerative disorders like Huntington’s disease or types of dementia without using expensive and invasive assessment techniques. Yet, by repeatedly recording and analysing the speech (how we speak, not what we say) of a patient, we build up a picture of how the brain is functioning and changing over time. This will lead to a more personalized approach with more effective treatments being given to the right patients at the right time.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Building and commercialising a digital speech tool (ADAAPT)
  • 批准号:
    nhmrc : GNT1153614
  • 项目类别:
    Development Grants
  • 资助金额:
    $93.27万
  • 财政年份:
    2019
  • 负责人:
    A/Pr Adam Vogel
  • 依托单位:
Optimising speech assessment and treatment in frontotemporal dementia
  • 批准号:
    nhmrc : GNT1135683
  • 项目类别:
    Boosting Dementia Research Initiative
  • 资助金额:
    $72.22万
  • 财政年份:
    2017
  • 负责人:
    A/Pr Adam Vogel
  • 依托单位:
Optimising speech assessment and treatment in frontotemporal dementia
  • 批准号:
    nhmrc : 1135683
  • 项目类别:
    Targeted Calls
  • 资助金额:
    $48.78万
  • 财政年份:
    2017
  • 负责人:
    A/Pr Adam Vogel
  • 依托单位:
Communication and swallowing outcomes in patients with acquired and progressive neurological disorders
  • 批准号:
    nhmrc : GNT1082910
  • 项目类别:
    Career Development Fellowships
  • 资助金额:
    $41.18万
  • 财政年份:
    2015
  • 负责人:
    A/Pr Adam Vogel
  • 依托单位:
国内基金
海外基金
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
  • 批准号:
    82372007
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    谢文晖
  • 依托单位: